×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GLUE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/21
08:09 pm
glue
Mixed data results for two Monte Rosa molecular glue degraders [Yahoo! Finance]
Low
Report
Mixed data results for two Monte Rosa molecular glue degraders [Yahoo! Finance]
3/21
03:17 pm
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $10.00. They now have an "equal weight" rating on the stock.
Low
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $10.00. They now have an "equal weight" rating on the stock.
3/20
08:14 pm
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.
High
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.
3/20
07:00 am
glue
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Low
Report
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
3/12
02:35 pm
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $19.00 price target on the stock.
Low
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $19.00 price target on the stock.
3/11
07:00 am
glue
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Low
Report
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
2/24
07:00 am
glue
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Medium
Report
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
1/10
07:00 am
glue
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Medium
Report
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
06:09 am
glue
Form EFFECT Monte Rosa Therapeutics,
Medium
Report
Form EFFECT Monte Rosa Therapeutics,
3/25
06:32 pm
glue
Form 4 Monte Rosa Therapeutics, For: Mar 24 Filed by: Leo Chandra P.
Medium
Report
Form 4 Monte Rosa Therapeutics, For: Mar 24 Filed by: Leo Chandra P.
3/20
09:37 am
glue
Form S-3 Monte Rosa Therapeutics,
Medium
Report
Form S-3 Monte Rosa Therapeutics,
3/20
09:13 am
glue
Form S-8 Monte Rosa Therapeutics,
Medium
Report
Form S-8 Monte Rosa Therapeutics,
3/20
09:05 am
glue
Form 10-K Monte Rosa Therapeutics, For: Dec 31
Medium
Report
Form 10-K Monte Rosa Therapeutics, For: Dec 31
3/20
07:04 am
glue
Form 8-K Monte Rosa Therapeutics, For: Mar 20
Low
Report
Form 8-K Monte Rosa Therapeutics, For: Mar 20
2/14
09:30 am
glue
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
Low
Report
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
2/4
03:46 pm
glue
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: